06:32 AM EDT, 10/15/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) signed a drug discovery and licensing agreement with U.S. artificial intelligence therapeutics company insitro to identify drug targets and develop treatments for metabolic dysfunction-associated steatohepatitis and cardiomyopathies. Under the deal, insitro's Virtual Human AI platform will be used to identify causal disease biology across both indications and advance AstraZeneca-nominated targets from discovery through to development candidate, according to a Thursday release. Insitro will receive an upfront payment of $40 million and is eligible for up to $1.46 billion in potential milestones, plus potential single-digit royalties on global commercial sales. AstraZeneca will have exclusive worldwide rights to advance the selected programs identified under the partnership.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.